ESTIMATING THE RISK OF BACTERAEMIA IN HOSPITALISED PATIENTS WITH PNEUMOCOCCAL PNEUMONIA

Prevalence and risk factors for bacteremia in community-acquired pneumonia: A systematic review and meta-analysis

BACKGROUND

Bacteremia represents a significant complication in patients with community-acquired pneumonia (CAP). Nonetheless, there is currently a dearth of systematic research that determines the precise prevalence and risk factors of bacteremia in CAP patients.

METHODS

PubMed, Cochrane Library, Embase, and Web of Science databases were searched for published studies on the prevalence or risk factors for CAP with bacteremia up to April 21, 2024. The NOS scale was utilized to appraise the study quality, and the META process was carried out in R language.

RESULTS

58,342 CAP patients were enrolled in 22 studies. Of these patients, 29,610 underwent blood culture tests, and 2332 patients had positive blood culture results. Meta-analysis pooled results showed that the incidence of bacteremia was 5.1% (95% CI: 3.6-6.8%) in CAP patients. The prevalence of co-bacteremia was 3.1% (95% CI: 1.5-5.1%) in minors and 6.9% (95% CI: 5.2%-8.8%) in adults. The most common pathogens of CAP were Streptococcus pneumoniae, Staphylococcus aureus. In addition, a summary of the original studies found that the risk factors for bacteremia in CAP patients were diverse and varied.

CONCLUSIONS

The incidence of bacteremia in CAP patients warrants significant attention. There is a pressing need to establish more specific bacterial screening protocols.

Incidence of Invasive and Noninvasive Pneumococcal Pneumonia Hospitalizations in People Aged ≥50 Years: Assessing Variability Across Denmark and Spain

Determining pneumococcal pneumonia (PP) burden in the elderly population is challenging due to limited data on invasive PP (IPP) and, in particular, noninvasive PP (NIPP) incidence. Using retrospective cohorts of adults aged ≥50 years in Denmark (2 782 303) and the Valencia region, Spain (2 283 344), we found higher IPP hospitalization rates in Denmark than Valencia (18.3 vs 9/100 000 person-years [PY], respectively). Conversely, NIPP hospitalization rates were higher in Valencia (48.2 vs 7.2/100 000 PY). IPP and NIPP rates increased with age and comorbidities in both regions, with variations by sex and case characteristics (eg, complications, mortality). The burden of PP in adults is substantial, yet its true magnitude remains elusive. Discrepancies in clinical practices impede international comparisons; for instance, Valencia employed a higher frequency of urinary antigen tests compared to Denmark. Additionally, coding practices and prehospital antibiotic utilization may further influence these variations. These findings could guide policymakers and enhance the understanding of international disparities in disease burden assessments.